FOXP3 and inflammatory bowel disease: The results of a multicenter phase I/IIa clinical trial indicate that the change in the balance between Foxp3 + CD4 + Treg cells and T effector cells in the intestinal microenvironment may be the cause of inflammatory bowel disease [142].